Delamanid

證據等級: L5

預測適應症: 7 個

Delamanid: From Tuberculosis (MDR-TB) to Bovine Tuberculosis

One-Sentence Summary

Delamanid is a nitro-dihydro-imidazooxazole antimycobacterial, publicly known as a treatment for multidrug-resistant tuberculosis (MDR-TB), though no formal indication text is present in this evidence pack. The TxGNN model predicts it may also be effective for Tuberculosis, Bovine (zoonotic Mycobacterium bovis infection), but currently no clinical trials and only 1 indirect publication support this specific direction.

Quick Overview

Item	Content
Original Indication	Not formally provided in this evidence pack. Delamanid is publicly known as an antimycobacterial approved for pulmonary MDR-TB; `original_indications` and `original_moa` fields are empty/Data Gap in the source data.
Predicted New Indication	Tuberculosis, Bovine
TxGNN Prediction Score	99.91%
Evidence Level	L5 (model prediction only — no clinical trial, and the single available paper does not evaluate delamanid's efficacy)
Germany Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this evidence pack (original_moa = Data Gap). Based on generally known information, delamanid is a nitro-dihydro-imidazooxazole derivative developed as an antimycobacterial agent, used clinically for multidrug-resistant pulmonary tuberculosis caused by Mycobacterium tuberculosis.

The predicted new indication, "tuberculosis, bovine," is caused by Mycobacterium bovis, a member of the Mycobacterium tuberculosis complex that is closely related to M. tuberculosis and shares similar drug-target biology. This makes the TxGNN prediction biologically plausible on a mechanistic level. However, it is worth noting that this is not a novel disease area so much as a related pathogen/host variant of the drug's already-established anti-tuberculosis use — the prediction largely reflects known pharmacology rather than a genuinely new therapeutic direction.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
39487429	2024	Observational / Genomic (WGS) study	BMC Genomics	Whole-genome sequencing study characterizing genetic diversity and drug-resistance patterns of M. bovis isolates in zoonotic TB; does not directly evaluate delamanid efficacy, but provides pathogen background relevant to treatment target.

Germany Market Information

Delamanid currently holds 0 marketing authorizations on record and has a market status of Not Marketed — no authorization table to display.

Safety Considerations

Please refer to the package insert for safety information.

Note: Formal safety data (warnings, contraindications, drug interactions) is not currently available in this dataset and is flagged as a Blocking data gap (DG001), preventing full S1 safety pre-assessment.

Conclusion and Next Steps

Decision: Hold

Rationale: The predicted indication is supported only by the TxGNN score and one tangential publication that does not test delamanid's efficacy; no clinical trials directly address bovine/zoonotic TB with this drug. A Blocking safety data gap (missing label warnings/contraindications) also prevents a proper safety pre-assessment.

To proceed, the following is needed:

Official label/package insert data (warnings, contraindications) — DG001
Confirmed mechanism of action from DrugBank — DG002
Direct evidence (in vitro/in vivo or clinical) evaluating delamanid specifically against M. bovis
Clarification of true novelty: assess whether "bovine tuberculosis" represents a distinct regulatory indication or overlaps with delamanid's existing MDR-TB approval
Confirmation of regulatory/market status before any repurposing pathway is pursued
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.